U.S. Food And Drug Administration Awards Additional Funding For QTORINTM Rapamycin For The Treatment Of Microcystic Lymphatic Malformations

(MENAFN - GlobeNewsWire - Nasdaq) NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORINTM rapamycin has ...